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Introduction
Inherited bone marrow failure syndromes (IBMFSs) are a 
group of congenital rare diseases with high genetic heterogene-
ity that are mainly characterized by bone marrow failure, phe-
notypic findings, and cancer predisposition.1,2 A large number of 
IBMFSs have been described so far, with Fanconi anemia (FA), 
dyskeratosis congenita (DC), Diamond-Blackfan anemia (DBA), 
and Shwachman-Diamond syndrome (SDS) being among the 
most common in this group of syndromes.3
The correct genetic diagnosis of IBMFSs is crucial to pre-
dict the disease course, to provide genetic counseling, and to 
select the most appropriate treatment, including hematopoietic 
stem cell transplantation (HSCT) from healthy donors. Many 
patients with IBMFSs remain underdiagnosed, mainly because 
Abstract 
Inherited bone marrow failure syndromes (IBMFSs) are a group of congenital rare diseases characterized by bone marrow failure, 
congenital anomalies, high genetic heterogeneity, and predisposition to cancer. Appropriate treatment and cancer surveillance 
ideally depend on the identification of the mutated gene. A next-generation sequencing (NGS) panel of genes could be 1 initial 
genetic screening test to be carried out in a comprehensive study of IBMFSs, allowing molecular detection in affected patients.  We 
designed 2 NGS panels of IBMFS genes: version 1 included 129 genes and version 2 involved 145 genes. The cohort included a 
total of 204 patients with suspected IBMFSs without molecular diagnosis. Capture-based targeted sequencing covered > 99% of 
the target regions of 145 genes, with more than 20 independent reads. No differences were seen between the 2 versions of the 
panel. The NGS tool allowed a total of 91 patients to be diagnosed, with an overall molecular diagnostic rate of 44%. Among the 
167 patients with classified IBMFSs, 81 patients (48%) were diagnosed. Unclassified IBMFSs involved a total of 37 patients, of 
whom 9 patients (24%) were diagnosed. The preexisting diagnosis of 6 clinically classified patients (6%) was amended, implying a 
change of therapy for some of them. Our NGS IBMFS gene panel assay is a useful tool in the molecular diagnosis of IBMFSs and a 
reasonable option as the first tier genetic test in these disorders.
13Vall d’Hebron Institut de Recerca, Barcelona, Spain
14Hospital Universitario Virgen de la Arrixaca, Murcia, Spain
15Unidad Pediátrica de Hematología, Oncología y TPH, Hospital de la Santa Creu 
i Sant Pau, Barcelona, Universidad Autònoma de Barcelona, Institut de Recerca 
del Hospital Sant Pau, Barcelona, Spain
16Servicio de Genética, Hospital de la Santa Creu i Sant Pau, Barcelona, 
Universidad Autònoma de Barcelona, Institut de Recerca del Hospital Sant Pau, 
Barcelona, Spain.
Supplemental digital content is available for this article.
Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc. 
on behalf of the European Hematology Association. This is an open-access 
article distributed under the terms of the Creative Commons Attribution-Non 
Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible 
to download and share the work provided it is properly cited. The work cannot be 
changed in any way or used commercially without permission from the journal.
HemaSphere (2021) 5:4(e539). http://dx.doi.org/10.1097/
HS9.0000000000000539.
Received: 14 September 2020 / Accepted: 11 January 2021
2
Gálvez et al Next-generation Sequencing in BMFS and Isolated Cytopenias
they are characterized by a wide range of syndromes and, 
at the same time, have a high degree of phenotypic overlap. 
Consequently, despite having an adequate clinical orientation 
based on the patient’s medical history and examination, it is 
possible that no conclusive diagnosis can be made in many of 
these patients.
Until recently, molecular diagnosis in clinical practice was 
limited to the conventional sequencing of the most frequently 
mutated genes, using techniques such as Sanger sequencing, 
based on clinical suspicion. However, nowadays, the large num-
ber of genes associated with IBMFSs makes mutation screening 
based on conventional techniques difficult, since gene-to-gene 
study strategies are expensive and slow.4 On the other hand, this 
approach is not applicable to disorders whose phenotype-based 
diagnosis is not straightforward and for which there is no obvi-
ous candidate gene.
The recent advent of next-generation sequencing (NGS) tech-
niques has begun to revolutionize the field of genetic diagnosis 
and is rapidly becoming established in clinical practice.5 These 
tools allow thousands of DNA fragments to be obtained in a 
single reaction, making it possible to analyze a high number 
of genes in a short period of time.6,7 NGS techniques include 
targeted gene sequencing (panels), whole-exome sequencing 
(WES), and whole-genome sequencing (WGS), each of them 
with distinct advantages and disadvantages. Compared with 
WES/WGS, targeted gene sequencing is a relatively inexpensive 
approach for identifying pathogenic mutations and has a rela-
tively higher sequence coverage.
The use of targeted sequencing or gene panels has already 
been used in genetically heterogeneous diseases, including 
IBMFSs.8–11 Most of these studies focused on specific syndromes, 
such as FA, DBA, or DC. Nevertheless, there are few published 
studies reporting the overall genetic diagnosis in heterogeneous 
groups of patients with IBMFSs. With respect to IBMFSs, NGS 
is emerging as a valuable tool for the molecular diagnosis of 
these disorders and is increasingly important as the first-line of 
the molecular diagnosis.12,13
Our hypothesis was that a panel of IBMFS genes could be 
used as an initial screening test to provide precise and clini-
cally relevant molecular diagnoses in a timely manner and at a 
reduced cost.
Herein, we report the design and implementation of a NGS 
platform for the genetic diagnosis in 204 patients with sus-
pected IBMFSs. The application of this approach has improved 
our diagnostic process, resulting in a molecular diagnosis in the 
largest series of patients with IBMFSs in Spain.
Materials and methods
Patients
A total of 214 consecutive patient samples from 47 Spanish 
centers were received between July 2015 and July 2018. Written 
informed consent for genetic investigation and research was 
provided by either the patients or their legal guardians. The 
sample collection process is described in Supplementary Figure 
S1 (http://links.lww.com/HS/A135).
All patients who were referred for suspected IBMFSs, accord-
ing to the criteria of the reference specialist, were included. 
Clinical data was received from each patient. These clinical data 
included the clinical suspicion, description of cytopenia/s, clin-
ical findings, family history, bone marrow investigations, and 
other investigations. The criteria used to define the suspicion of 
an IBMFS are described in Supplementary Table S1 (http://links.
lww.com/HS/A135).
Clinical diagnostic suspicions included DBA, FA, DC, SDS, 
congenital amegakaryocytic thrombocytopenia (CAMT), hered-
itary thrombocytopenia (HT), severe congenital neutropenia 
(SCN), myelodysplastic syndrome (MDS), other cytopenia, and 
other IBMFSs. Depending on the clinical suspicion, the patients 
were divided into 2 groups: group 1 included those referred for 
a suspected classified IBMFS (DBA, FA, DC, SDS, HT, SCN, or 
MDS; Table 1) and group 2 included all those referred for unclas-
sified IBMFSs (other cytopenia and other IBMFSs; Table 2).
NGS gene panel assay
DNA was extracted from peripheral blood following rou-
tine methods. We designed an NGS assay for a comprehensive 
panel of 145 IBMFS genes published as of September 2016. We 
devised 2 versions of the panel: version 1 (v1) included a total 
of 129 IBMFS genes and version 2 (v2) was updated to include 
16 further genes (Supplementary Table S2, http://links.lww.com/
HS/A135). Detailed panel design and bioinformatic analysis are 
presented in Additional file 1: Supplemental Material (http://
links.lww.com/HS/A135).
Strategy used for copy number variant analysis
Copy number variation (CNV) was detected with an in-house 
tool (LACONv) that is based on GC-correction followed by a 
normalized weighted ratio of depth-of-coverage with respect to 
controls. The tool was optimized for targeted capture sequenc-
ing and CNV intervals were determined if “dose” value and its 
z value were above/below some threshold that was adjusted 
experimentally with a reference set. The CNVs of each patient 
were analyzed and those deletions/insertions detected were con-
firmed using other techniques (multiplex ligation-dependent 
probe amplification [MLPA] and comparative genomic hybrid-
ization [CGH] arrays).
Variant analysis and filtering strategy
The variant analysis and filtering strategy followed the guide-
lines of the American College of Medical Genetics and Genomics 
(ACMG)14 and the publications previously reported.12,13,15
The variants that were previously reported to be pathogenic 
or disease causing in public databases (Supplementary Table 
S3, http://links.lww.com/HS/A135). These variants were clas-
sified according to the ACMG guidelines into 5 groups: likely 
benign, benign, variants of unknown significance (VUS), likely 
pathogenic, and pathogenic. Those variants classified as benign 
or possibly benign were not considered as causative. The other 
variants classified as VUS, likely pathogenic, and pathogenic 
were discussed with physicians who were experts in that par-
ticular disease area, and genetic diagnoses were made based on 
the mode of inheritance of each disease, type of mutation, and 
patient’s clinical findings. All variants detected were validated by 
Sanger sequencing. family studies were performed to determine 
the segregation or “de novo” origin of the detected variants. The 
algorithm used to filter variants is described in Figure 1.
Results
Quality parameter analysis and variant detection
Capture-based targeted sequencing covered > 99% of the tar-
get regions of 145 genes, with more than 20 independent reads. 
DDX11 and RPS17 did not reach the quality criteria, because 
the capture-based targeted sequencing of these genes covered 
< 80%. The average read depth was 367x (0–637). In addition, 
95% of the targeted regions were covered > 50x. Variants identi-
fied in v1 included in group A and those considered as probable 
causative variants included in group B were validated through 
Sanger sequencing. Among the 214 patient’s cohort, 10 were 
positive controls (Supplementary Table S4, http://links.lww.
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com/HS/A135). All the positive control’s variants were detected 
by the NGS assay.
We identified 104 variants in 90 patients with no previous 
molecular diagnosis. Using v1, we detected 58 variants in 47 
patients, and using v2, we detected 46 variants in 43 patients.
Among the 104 detected variants, 56 variants had previ-
ously been reported and 48 variants were novel. The variants 
were classified according to the ACMG guidelines. We detected 
11 pathogenic variants, 12 likely pathogenic variants, and 25 
VUS. Regarding the mutation type of all variants, 50 were 
missense, 30 were indels, 14 were splicing variants, and 10 
were nonsense.
Genetic diagnosis by targeted sequencing in the 
total group
Of the 204 patients with IBMFSs with no molecular diag-
nosis, we detected pathogenic variants in 90 patients (44%). 
We included a total of 104 samples in v1 and 100 samples in 
Table 1
Genotyping Patients With classified IBMFSs (Group 1).
Clinical Diagnosis
No. Patients  
Tested




No. Cases With  
Mutations in This Gene
No. Mutations  
in This Gene
Novel Mutations  
in This Gene
Diamond-Blackfan anemia 45 31 RPL11 8 8 4
RPL5 6 6 6
RPS19 6 6 0
RPS24 1 1 1
RPS26 5 5 2
RPS29 2 2 2
RPS7 2 2 2
Del 15q 1 1 0
Dyskeratosis congenita 12 8 DKC1 3 3 1
RTEL1 3 4 2
TERT 2 2 1
Fanconi anemia 28 16 FANCA 13 19 3
FANCB 1 1 1
FANCG 2 3 0
Hereditary thrombocytopenia 38 16 ANKRD26 1 1 1
CYCS 2 2 2
GP1BA 2 2 2
ITGA2B 1 1 1
ITGB3 2 2 2
MYH9 5 5 0
RBM8A 1 2 1
TUBB1 1 1 1
WAS 1 1 1
Severe congenital neutropenia 25 3 ELANE 1 1 0
JAGN1 1 1 0
TCIRG1 1 1 1
Myelodysplastic syndrome 5 3 RPL11 1 1 0
TERT 1 1 0
CEBPA 1 1 1
Shwachman-Diamond syndrome 6 1 SBDS 1 2 0
Congenital amegakaryocytic thrombocytopenia 5 2 MPL 1 1 1
TERT 1 1 0
Other congenital anemia 3 1 KLF1 1 1 1
IBMFS = inherited bone marrow failure syndrome.
Table 2
Genotyping Patients With Unclassified IBMFSs (Group 2).
Clinical Diagnosis
No. Patients  
Tested




No. Cases With Mutations  
in This Gene
No. Mutations  
in This Gene
Novel Mutations  
in This Gene Final Diagnosis
Aplastic anemia 2 2 FANCA 1 2 1 Fanconi anemia
TINF2 1 1 0 Dyskeratosis congenita
Bilineage cytopenia 2 2 RECQL4 1 2 0 Rothmund-Thomson syndrome
MPL 1 2 2 CAMT
Bone marrow failure 21 4 AP3B1 1 1 1 Hermansky-Pudlak syndrome 
type 2
MPL 1 1 1 CAMT
PUS1 1 1 1 Sideroblastic anemia
G6PC3 1 1 1 Dursun syndrome
Trilineage cytopenia 3 1 TERT 1 1 1 Dyskeratosis congenita
CAMT = congenital amegakaryocytic thrombocytopenia; IBMFS = inherited bone marrow failure syndrome.
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v2, with diagnostic rates of 45% (47/104) and 43% (43/100), 
respectively. We detected pathogenic variants in 35 genes. 
FANCA was the most frequently recognized gene with patho-
genic variants, which was identified in 13 patients.
Genetic diagnosis by targeted sequencing in the 
classified IBMFS group (group 1)
This group included 167 patients with a suspected classi-
fied IBMFS and no molecular diagnosis (Supplementary Table 
S5, http://links.lww.com/HS/A135). We calculated genetic 
diagnostic rates through our targeted sequencing pipeline, 
taking into account the estimated mode of inheritance. The 
genetic diagnosis of patients with a clinical diagnosis of DBA 
(31/45, 68%), DC (8/12, 66%), MDS (3/5, 60%), and FA 
(16/28, 57%) was achieved in more than half of the patients. 
The genetic diagnostic rates for other categories were as fol-
lows: SCN (3/25, 12%), HT (16/38, 45%), SDS (1/6, 16%), 
CAMT (2/5, 40%), and other congenital anemias (1/3, 33%). 
In total, our targeted sequencing pipeline diagnosed 81 of 
167 patients (48%) in the classified IBMFS group. Regarding 
the panel version, in the classified IBMFS group, we achieved 
a diagnostic rate of 56% (47/84) in the v1 panel and 47% 
(39/83) in the v2 panel.
In this group, we identified copy number aberrations in 2 
patients. Patient 02021 had a positive chromosomal breakage 
test with no mutation detected by the NGS panel assay. A sig-
nificant deletion was detected by the CNVs analysis from exon 
9 to 43 of the FANCA gene (Supplementary Figures S2 and S3, 
http://links.lww.com/HS/A135). This deletion was confirmed by 
MLPA in the patient and parents. The mother carried a deletion 
from exon 9 to 15 of the FANCA gene, and her father carried a 
deletion from exon 16 to 43 of the same gene (Supplementary 
Figures S4–S6, http://links.lww.com/HS/A135).
The second case (patient 10002) involved a patient with 
thrombocytopenia and bilateral malformations of the radii 
at birth. In the NGS study, *6C>G on the RBM8A gene was 
detected, with an allelic frequency of 80%. The presence of this 
mutation in homozygosis was confirmed by Sanger sequencing 
(Supplementary Figure S7, http://links.lww.com/HS/A135). The 
study of CNVs performed by NGS therefore showed a signifi-
cant deletion in chromosome 1 that included the RBM8A gene 
(Supplementary Figure S8, http://links.lww.com/HS/A135). 
After performing the single-nucleotide polymorphism microar-
ray study, the presence of a microdeletion on chromosome 1 
was demonstrated, from position 145395440 to 146089268 
(Supplementary Figure S9, http://links.lww.com/HS/A135). The 
same study was subsequently carried out on the patient’s parents 
using NGS, and it was observed that the *6C>G change on the 
RBM8A gene was present in the patient’s father (Supplementary 
Figure S10, http://links.lww.com/HS/A135). The CNV study 
showed a deletion in chromosome 1 in the patient’s mother, 
which included the RBM8A gene (Supplementary Figure S11, 
http://links.lww.com/HS/A135). Finally, patient 10002 was 
diagnosed with thrombocytopenia-absent radius syndrome 
associated with pathogenic variants of the RBM8A gene.16
Genetic diagnosis by targeted sequencing in the 
unclassified IBMFS group (group 2)
We included 37 patients with unclassified IBMFSs 
(Supplementary Table S6, http://links.lww.com/HS/A135). We 
identified 13 variants in 9 patients, with a diagnostic rate of 
24% (9/37) in this group (Table 2). With regard to the panel 
version, we achieved a diagnostic rate of 17% (5/28) in v1 and 
44% (4/9) in v2.
Of the 9 patients in whom pathogenic variants were detected, 
5 patients were diagnosed with typical IBMFSs. Patients 12006 
Figure 1. Algorithm summarizing analysis and filtering processes (American College of Medical Genetics and Genomics [ACMG]).
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and 08001 were diagnosed with DC, having mutations in the 
TINF2 and TERT genes, respectively. Patients 23001 and 
10003 were diagnosed with CAMT, having MPL gene muta-
tions in both cases. Patient 04016 was diagnosed with FA with 
compound heterozygosis of the FANCA gene.
The other 4 patients were diagnosed with other less com-
mon syndromes. Two of the successfully genotyped patients 
with unclassified IBMFSs had predominant neutropenia. Patient 
40004 had a homozygous pathogenic variant of the G6PC3 
gene, which is associated with the development of Dursun syn-
drome.17 In the other case, patient 20001, the mutation was 
detected in the AP3B1 gene associated with Hermansky-Pudlak 
syndrome type 2.18
The last 2 patients diagnosed in this group were 11029 and 
01015, who were diagnosed with Rothmund-Thomson syn-
drome and sideroblastic anemia with pathogenic variants of the 
RECQL4 and PUS1 genes, respectively.
Diagnostic amendments
The diagnosis of 6 clinically classified patients (6%) was 
amended after the results of the NGS gene panel assay became 
available.
The first example involved 2 patients clinically diagnosed with 
aplastic anemia (AA) based on hematological findings. In 1 of 
them (patient 12006, 4 years old), we found a pathogenic vari-
ant of TINF2 (c.815G>A),19 which produced a stop codon. In 
view of the results, a telomere length study was carried out and 
very short telomeres were detected (<p1). Accordingly, the diag-
nosis was amended to DC. The second patient (patient 04016) 
had been clinically diagnosed with AA and was unresponsive to 
immunosuppressive therapy. In this study, we found 2 heterozy-
gous pathogenic changes of the FANCA gene (c.1115_1118del 
and c.2303T>C).20,21 The chromosomal breakage test came back 
positive, so the patient was finally diagnosed with FA.
Patients 40001 and 38001 were eventually diagnosed with 
DC. Based on their clinical evolution and hematological find-
ings, patients 40001 and 38001 were initially referred for sus-
pected CAMT and for suspected myelodysplasia, respectively. 
However, in both cases, the study showed mutations associated 
with the development of DC on the TERT gene (c.2225G>A and 
c.1234C>T, respectively). Both mutations have been previously 
described in the literature.22,23 DC was confirmed by a telomere 
length study of these patients, with both cases presenting with 
telomere shortening below the first percentile for their age.
The last 2 patients included in this group were eventually 
diagnosed with DBA. Patient 04006, aged 7 years, was stud-
ied for an episode of transient thrombocytopenia; however, 
a c.164C>T pathogenic variant was detected on the RPS19 
gene, which was associated with the development of DBA.24 
Reviewing the clinical history of patient 04006, it seems that, 
in early childhood, he had an episode of severe anemia but pro-
gressively recovered until reaching his present level of 10 g/dL of 
hemoglobin. Patient 10013, aged 23 years, had been studied for 
mild anemia from childhood with features of myelodysplasia in 
the bone marrow study performed in adulthood. This patient 
had a deletion on the RPL11 gene, which has already been 
described as causing DBA.25
Analysis of undiagnosed patients
Of the 204 patients analyzed with NGS, a total of 113 patients 
were not diagnosed, corresponding to 55% of the total sample. 
Two years after the recruitment of these patients, the doctors 
responsible for monitoring the clinical evolution of the patients 
were questioned again. Among these 113 patients, it was pos-
sible to record the follow-up of 105 patients (Figure 2); 70% 
of these patients (75/105) presented with no significant clinical 
changes and no molecular diagnosis had been achieved, with 
IBMFSs still suspected. Of the remaining 30 patients, 3 patients 
proceeded to HSCT, 1 of whom died due to complications 
following the procedure. In 4 cases, a molecular diagnosis of 
IBMFS had been made using the other techniques summarized 
in Table 3. Three patients had had spontaneous hematological 
recovery without treatment, and the remaining 20 patients had 
been reclassified as having other noncongenital diseases. The 
majority of patients (12 cases) were reclassified as immune 
cytopenias, and the remaining patients were distributed heter-
ogeneously: AA (3 cases), immunodeficiency (2 cases), pyruvate 
kinase deficiency (1 case), myeloproliferative syndrome (1 case), 
and mitochondrial disease (1 case).
Discussion
In recent years, the identification of the underlying molecular 
pathology has become the cornerstone for establishing a con-
clusive diagnosis of IBMFS, leading to better clinical care and 
follow-up of these patients. Until recently, Sanger sequencing of 
candidate genes has been the gold standard tool for the genetic 
diagnosis of IBMFS, resulting in a costly and lengthy technique.4 
In 2015, NGS techniques emerged as the herald of the revolu-
tion in the genetic diagnosis of IBMFSs.12,13,15,26
In this study, we have reached the molecular diagnosis of 
a cohort of patients from hospitals in Spain with suspected 
IBMFSs using a NGS assay, for which we developed a molecular 
diagnostic system that utilized a targeted sequencing pipeline 
covering 145 IBMFS genes. During the study, we have only had 
access to samples from peripheral blood. However, studies of 
family segregation have been carried out, which has supported 
the interpretation of the origin of the detected variants. We first 
performed a validation study of previously ascertained genetic 
variants, which confirmed the strong analytical sensitivity and 
reproducibility of the platform. We detected 11 known variants 
in 7 genes, including missense and nonsense variants and small 
deletions from 10 patients.
In this series of patients, we identified 104 candidate vari-
ants in 35 genes, 46% of which were absent from the main 
reference databases, thus emphasizing the great heterogeneity 
of the molecular pathology underlying IBMFSs. Appropriate 
interpretation of the pathogenicity of candidate genetic vari-
ants found by NGS remains a major challenge, especially for 
novel variants, even if present in well-established IBMFS genes. 
To prevent misinterpretation, the use of consensus guidelines is 
highly recommended, although there is significant discordance 
between laboratories.14,27 Following established guidelines and 
studies carried out by other groups, we have designed our own 
variant-filtering strategy carrying out the same analysis for each 
variant.12–14 Finally, of the 104 identified candidate variants, we 
classified 23% and 25% as pathogenic and likely pathogenic, 
respectively. Approximately half of the variants were classified 
as VUS. The high proportion of VUS supposes 1 of the major 
limitations of the study, since we did not have the possibility to 
carry out functional studies. However, through the family study 
and after evaluating each of the cases with the responsible spe-
cialist, we analyzed the clinical picture of the patient, the mode 
of inheritance of each disease, and the characteristics of the 
variants. Therefore, as changes are compatible with the clinical 
picture of the patients, we interpret that these variants could 
have an important role in the development of the disease. These 
results indicate the great complexity to interpret variants in this 
type of disease and, at the same time, reflect the need to deepen 
the knowledge of the molecular bases of IBMFSs to be able to 
assess their involvement in the development of the disease.
Overall, our NGS approach enabled a molecular diagnosis in 
44% of patients. The diagnostic rate of our targeted sequencing 
platform was similar to those obtained by other groups. The 
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previous studies published by Ghemlas et al12 and Muramatsu 
et al,13 which involved similar approaches, studied patients with 
suspected IBMFSs using a NGS assay and analyzed the diagnos-
tic yield. The first work published by Ghemlas et al12 diagnosed 
61 of the 158 patients studied using a panel of 72 genes, with 
an overall diagnostic rate of 38%. The report by the Japanese 
group studied diagnostic rates in a population of patients using 
a NGS panel and WES. With targeted sequencing, this group 
achieved a genetic diagnosis rate of 53 out of 121 (44%).
In our study, we analyzed the results according to the groups 
into which the patients were divided. The percentage of diagno-
ses achieved in the classified IBMFS group was 48% (81/167) 
compared with 24% (9/37) in the unclassified IBMFS group. 
Remarkably, the diagnostic rate was higher for patients present-
ing with a well-defined clinical phenotype indicative of a partic-
ular type of IBMFS. The Canadian group of Ghemlas et al12 also 
used this division, observing a similar disparity, with a molec-
ular diagnosis rate of 59% in the case of classified IBMFSs, 
compared with 18% for unclassified IBMFSs. This difference 
suggests that, for cases of clinically well-defined diseases with 
specific screening analysis (such as chromosomal breakage test, 
telomere length, or biochemical characteristics), the diagnostic 
rate is acceptable; nevertheless, for patients with more complex 
phenotypes, diagnosis using a NGS gene panel may be insuffi-
cient. This is supported by 1 of the first papers published in this 
field. Zhang et al15 used a NGS panel of 85 genes to study a 
total of 71 patients affected by IBMFSs with no typical clinical 
characteristics. The author described the molecular basis of 8 of 
the 71 patients, with a diagnostic rate of 11%. These 8 patients 
presented pathogenic variants in the GATA2, RUNX1, DKC1, 
and LIG4 genes but did not present the typical phenotypic 
characteristics associated with these genes. This illustrates the 
fact that the molecular diagnosis of unclassified IBMFSs using 
a NGS gene panel does not exceed 20%, suggesting that this 
group could benefit from other approaches. Data provided by 
Bluteau et al28 support this idea. These authors studied a total 
of 179 samples from patients with suspected IBMFSs without 
a defined clinical phenotype, excluding those with characteris-
tics of FA, DBA, DC, SDS, and SCN. For all the samples, WES 
of the DNA extracted from fibroblasts was undertaken, so all 
samples corresponded to the germ line. Finally, a total of 86 
patients were diagnosed, with a diagnostic rate of 48%. This 
data exceeds the results obtained using NGS panels, which 
seems to indicate that WES of germline samples is an interesting 
Figure 2. Description of clinical evolution in undiagnosed patients. HSCT = hematopoietic stem cell transplantation.
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tool to be considered for patients who do not present with typi-
cal clinical characteristics.
Regarding to specific groups, in this series, the diagnostic 
yield in FA group had been 57%, being lower than expected. 
This could be explained by patient selection. All referred 
patients were included in this study and, in some cases, the 
chromosomal breakage test had not been performed. Therefore, 
probably some patients were affected by another syndrome, no 
FA. However, 87% (14/16) patients with positive chromosomal 
breakage test were diagnosed using the NGS platform, being 
the diagnostic rate of this approach higher in patients with a 
positive chromosomal breakage test.
In SDS group, only 1 patient was diagnosed by NGS. The 
explanation could lie in the previous genetic studies performed 
before they were included in the study. When this NGS panel 
was designed, the only SBDS gene had been associated with the 
development of this disease, so of the 5 patients without molecu-
lar diagnosis, 3 of them were negative for this gene. Throughout 
the development of this project, new genes associated with 
this disease have been described, specifically DNAJC2129,30 
and EFL131. In 1 of the patients in whom no result was found, 
WES was subsequently performed, detecting DNAJC21 gene 
mutated. Therefore, we could say that those patients highly sug-
gestive of SDS negatives for the SBDS gene could not benefit 
from approaches using NGS panels that are not updated.
In this work, 2 versions of the same panel were used, with 
129 genes included in v1 and 145 genes included in v2. The 
percentage of molecular diagnosis achieved for the 2 versions 
did not differ substantially (45% in v1 versus 43% in v2), which 
may suggest that the number of genes included per panel was 
not decisive in the percentage of diagnoses achieved by this 
tool. One possible explanation is that the panels that include a 
greater number of genes are those that have been designed more 
recently, including recently discovered genes that have been 
described with a lower frequency. Since this approach is some-
what similar to screening, it is likely that, for the vast majority 
of patients, the mutations fall within the group of genes most 
frequently detected in patients with IBMFSs. However, gene 
panels require periodic updating to ensure they cover as many 
genes as possible, thus optimizing molecular diagnosis.
In most patients diagnosed, the clinical suspicion coincided 
with the molecular diagnosis. However, it is important to high-
light the fact that 6 of the 91 patients diagnosed (6%) were 
reclassified, implying a change in their clinical management. In 
this work, the rate of diagnostic amendments is somewhat lower 
than that published for other series, where the rate is around 
10%–26%.12,13,32 However, even if the number is not high, it has 
very important clinical implications, such as avoiding unneces-
sary treatments or giving adequate genetic counseling. In 1 case, 
the clinical diagnosis of AA was amended to FA, meaning the 
convenience of entering into a bone marrow transplant proce-
dure because of the high risk of progressing to MDS/AML and 
periodic monitoring for early detection of cancer, specifically in 
the head and neck, which are the most prevalent types in this 
disease.28 Patients diagnosed with DC should have long-term 
follow-up to monitor the onset of bone marrow failure, as well 
as the development of pulmonary or hepatic fibrosis or the 
appearance of cancer. Another example was the patient under 
study for mild thrombocytopenia who was finally diagnosed 
with DBA. This finding implied the convenience of performing 
close monitoring of the patient due to the increased risk of can-
cer in patients with DBA. Therefore, in addition to the specific 
treatment that the development of anemia would require, it is 
advisable that these patients should follow an early detection 
program in adulthood.
In this work, there was no particular selection of the patient 
cohort. The selection criteria were less strict than for other 
groups, so it would be expected that a percentage of the patients 
were not affected by a congenital disease. Based on this premise, 
the reference specialist doctors responsible for monitoring the 
clinical evolution of the patients were questioned 2 years after 
their patients had been included in this study. After this consul-
tation, 24 patients did not meet the clinical criteria for a IBMFS, 
and some experienced spontaneous hematological remission. 
Therefore, it seems reasonable to establish a series of minimum 
criteria, both clinical and analytical, before applying this type of 
diagnostic approach.
Using this approach, we have detected variants potentially 
responsible of the phenotype in only half of the patients. This 
could be due to the technical limitations inherent in this type of 
diagnostic approach, such as mutations in deep intronic areas 
or genes for which there was not sufficient depth of reading. 
Additionally, problems of bioinformatic tools determining the 
pathogenicity of rare variants or incomplete knowledge of the 
IBMFSs may have accounted for these limitations. NGS can 
miss large deletions or duplications; CNVs involving > 1000 bp; 
or large structural chromosomal variants, translocations, and 
aneuploidy unless they have been specifically designed for such 
a purpose.29 Thus, for successful molecular diagnosis of certain 
cases, the NGS assay should be combined with other molecular 
approaches, such as CGH array, quantitative polymerase chain 
reaction, or MLPA.
Possibly the greatest limitation for detecting molecular 
alterations using a NGS panel of already defined genes is the 
progressive discovery of new IBMFS genes. Indeed, since the 
design of this panel, new genes have been discovered. In this 
work, there are 2 patients who have been diagnosed by WES 
for genes not included in this panel, such as DNAJC21 and 
SAMD9, published in 2017.14,30,31,33 The best option could be to 
use an updated panel as initial screening and subsequently select 
those patients who might be candidates for WES or even WGS. 
However, even with WES and WGS techniques, a percentage of 
patients are still not diagnosed.
In summary, our NGS gene panel assay constituted a useful 
tool for the genetic diagnosis of IBMFSs. The correct classifi-
cation of IBMFSs using NGS facilitates more accurate medical 
management of these complex conditions. Specifically, our gene 
panels were able to identify the genetic alterations in a high per-
centage of patients and constituted a reasonable option for the 
genetic screening of IBMFSs prior to the application of more 
complex studies, including WES and WGS, which might facili-
tate the discovery of new genes.
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